Roche's fenebrutinib significantly reduced relapses in RMS

AI Briefing

• – Roche's fenebrutinib effective in reducing relapse risk in rheumatoid arthritis patients
• – Fenebrutinib shows significant clinical benefit in RMS patients
• – New treatment option offers improved quality of life for patients with rheumatoid arthritis